20 completed, 2 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 7 Phase 3, 4 Phase 1, 3 Phase 2, 2 Phase 4.
By phase and status
Follow Growth Hormone Deficiency in Children: new trials by email Literature Review of Growth Hormone Deficiency in Children trials Research Report on Growth Hormone Deficiency in Children
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
GB06, Norditropin®FlexProTM - Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children | Phase 3 | Recruiting | Kexing Biopharm Co., Ltd. | 192 | 2026-06-06 | 2026-06-10 |
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
GB08, Norditropin NordiFlex - Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD) | Phase 2 / Phase 3 | Not yet recruiting | Shenzhen Kexing Pharmaceutical Co., Ltd. | 268 | 2025-08-31 | 2025-08-22 |
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
Somapacitan - Growth Hormone Deficiency in Children | | Enrolling by invitation | Novo Nordisk A/S | 200 | 2023-10-04 | 2026-04-29 |
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
somapacitan, Norditropin® - Growth Hormone Deficiency in Children | Phase 3 | Completed | Novo Nordisk A/S | 110 | 2021-07-22 | 2026-01-06 |
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
Norditropin® FlexPro® - Growth Hormone Deficiency in Children, Born Small for Gestational Age | | Enrolling by invitation | Novo Nordisk A/S | 750 | 2019-06-21 | 2026-10-08 |
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Somapacitan, Norditropin® - Growth Hormone Deficiency in Children | Phase 3 | Completed | Novo Nordisk A/S | 200 | 2019-05-20 | 2026-10-22 |
Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy
No treatment given - Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 321 | 2018-10-02 | 2019-09-23 |
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 34 | 2017-08-16 | 2019-05-24 |
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 44 | 2017-06-20 | 2020-04-17 |
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
somapacitan, Norditropin® FlexPro® pen - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 2 | Completed | Novo Nordisk A/S | 76 | 2016-03-31 | 2026-01-16 |
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
No treatment given - Growth Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 252 | 2015-10-05 | 2020-09-25 |
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
somapacitan, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 1 | Completed | Novo Nordisk A/S | 32 | 2013-12-16 | 2020-12-24 |
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
somapacitan, placebo (somapacitan) - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 105 | 2012-01-16 | 2020-12-24 |
Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone
Norditropin NordiFlex® - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 77 | 2011-04-01 | 2014-06-24 |
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Norditropin NordiFlex® - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 4 | Completed | Novo Nordisk A/S | 103 | 2010-11-01 | 2017-02-27 |
An Observational Study on Treatment Compliance by Children Treated With Growth Hormone
No treatment given - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Withdrawn | Novo Nordisk A/S | | 2010-02-01 | 2014-06-26 |
A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone
NNC126-0083, somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | Phase 2 | Completed | Novo Nordisk A/S | 31 | 2009-08-01 | 2017-02-08 |
Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™
NordiFlex PenMate™ - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 84 | 2007-01-01 | 2016-11-17 |
Observational Prospective Study on Patients Treated With Norditropin®
somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 21249 | 2006-04-01 | 2017-10-12 |
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
somatropin - Growth Hormone Disorder, Growth Hormone Deficiency in Children | | Completed | Novo Nordisk A/S | 2016 | 2005-05-01 | 2015-07-03 |
Showing 20 of 25. Sign in to see all of them.
Narrower conditions
Dwarfism, Pituitary (6) · Genetic Diseases, Inborn (6) · Turner Syndrome (6) · Growth Disorders (3) · Renal Insufficiency, Chronic (3) · Noonan Syndrome (1)
Broader conditions
Endocrine System Diseases (11) · Bone Diseases (6) · Bone Diseases, Developmental (6) · Bone Diseases, Endocrine (6) · Brain Diseases (6) · Cardiovascular Abnormalities (6) · Cardiovascular Diseases (6) · Central Nervous System Diseases (6) · Chromosome Disorders (6) · Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Disorders of Sex Development (6) · Dwarfism (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6)
Interventions
Human Growth Hormone (11) · somapacitan (8) · NNC0195-0092 (3) · Growth Hormone (2) · NNC126-0083 (1)
Sponsors
Novo Nordisk A/S (23) · Kexing Biopharm Co., Ltd. (1) · Shenzhen Kexing Pharmaceutical Co., Ltd. (1)
Countries
Germany (9) · France (7) · Israel (6) · Slovenia (5) · United States (5) · Belgium (4) · Japan (4) · Spain (4) · Sweden (4) · United Kingdom (4) · Austria (3) · China (3) · Denmark (3) · Norway (3) · Switzerland (3)
Top investigators
Junfen Fu (1) · Yijia Zhang (1)
Results publications
PMID 29671202, PMID 33754315, PMID 33864240, PMID 17356043, PMID 21724838, PMID 22508317, PMID 22788856, PMID 23658497, PMID 23737664, PMID 25013997, PMID 26903552, PMID 27280591, PMID 27736009, PMID 28522645, PMID 28656605, PMID 31305924, PMID 31917835, PMID 31972476, PMID 32158432, PMID 33433896, PMID 33571362, PMID 33709288, PMID 34964458, PMID 36062966, PMID 36255609, PMID 36947589, PMID 36995872, PMID 37406251, PMID 38066644, PMID 38368603, PMID 40400262, PMID 40919719, PMID 42369274
NIH funding
2008 (2), 2016 (2), 2009 (1), 2015 (1), 2018 (1)